NasdaqCM:ORGS

Stock Analysis Report

Executive Summary

Orgenesis Inc., a biotechnology company, engages in the development, manufacturing, and provision of services in the cell and gene therapy industry.


Snowflake Analysis

Mediocre balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has Orgenesis's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ORGS's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

6.8%

ORGS

4.7%

US Biotechs

7.2%

US Market


1 Year Return

-36.3%

ORGS

1.8%

US Biotechs

-10.4%

US Market

Return vs Industry: ORGS underperformed the US Biotechs industry which returned 1.8% over the past year.

Return vs Market: ORGS underperformed the US Market which returned -10.4% over the past year.


Shareholder returns

ORGSIndustryMarket
7 Day6.8%4.7%7.2%
30 Day-23.4%-3.5%-12.6%
90 Day-29.0%-5.4%-19.4%
1 Year-36.3%-36.3%2.6%1.8%-8.5%-10.4%
3 Year-68.3%-68.3%14.0%11.1%15.8%8.3%
5 Year-56.2%-56.2%-3.6%-7.9%35.8%21.0%

Price Volatility Vs. Market

How volatile is Orgenesis's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Orgenesis undervalued compared to its fair value and its price relative to the market?

11.1x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ORGS's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ORGS's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ORGS is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: ORGS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ORGS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ORGS is overvalued based on its PB Ratio (11.1x) compared to the US Biotechs industry average (2.6x).


Next Steps

Future Growth

How is Orgenesis forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

18.5%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if ORGS's forecast earnings growth is above the savings rate (1.7%).

Earnings vs Market: Insufficient data to determine if ORGS's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if ORGS's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if ORGS's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ORGS's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Orgenesis performed over the past 5 years?

-40.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ORGS is currently unprofitable.

Growing Profit Margin: ORGS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ORGS is unprofitable, and losses have increased over the past 5 years at a rate of -40.7% per year.

Accelerating Growth: Unable to compare ORGS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ORGS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22%).


Return on Equity

High ROE: ORGS has a negative Return on Equity (-70.32%), as it is currently unprofitable.


Next Steps

Financial Health

How is Orgenesis's financial position?


Financial Position Analysis

Short Term Liabilities: ORGS's short term assets ($26.0M) do not cover its short term liabilities ($31.6M).

Long Term Liabilities: ORGS's short term assets ($26.0M) exceed its long term liabilities ($23.9M).


Debt to Equity History and Analysis

Debt Level: ORGS's debt to equity ratio (39.3%) is considered satisfactory.

Reducing Debt: ORGS had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet

Inventory Level: ORGS has a high level of physical assets or inventory.

Debt Coverage by Assets: ORGS's debt is covered by short term assets (assets are 1.8x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ORGS has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ORGS has less than a year of cash runway if free cash flow continues to reduce at historical rates of -50.4% each year


Next Steps

Dividend

What is Orgenesis's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ORGS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ORGS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ORGS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ORGS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ORGS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.4yrs

Average management tenure


CEO

Vered Caplan (50yo)

6.25s

Tenure

US$1,398,056

Compensation

Ms. Vered Caplan, M.Sc., has been the President and Chief Executive Officer of Orgenesis Inc. since August 14, 2014. Ms. Caplan is the Sole Owner of PBD Ltd. Ms. Caplan has been the Chief Executive Officer ...


CEO Compensation Analysis

Compensation vs Market: Vered's total compensation ($USD1.40M) is above average for companies of similar size in the US market ($USD602.37K).

Compensation vs Earnings: Vered's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Vered Caplan
Chairperson of the Board6.25yrsUS$1.40mno data
Neil Reithinger
CFO, Secretary & Treasurer5.58yrsUS$236.62kno data
Denis Bedoret
President of Masthercell Global1.17yrsUS$321.36kno data
Darren Head
Chief Executive Officer of Masthercell Global1.17yrsUS$491.74kno data
Sarah Ferber
Founder & Chief Scientific Officerno dataUS$268.78kno data

3.4yrs

Average Tenure

50yo

Average Age

Experienced Management: ORGS's management team is considered experienced (3.4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Vered Caplan
Chairperson of the Board6.25yrsUS$1.40mno data
Guy Yachin
Independent Director7.83yrsUS$157.00kno data
Jay Skyler
Scientific Advisor6.83yrsUS$9.41kno data
David Sidransky
Independent Director6.67yrsUS$181.12kno data
Itamar Raz
5yrsno datano data
Yaron Adler
Independent Director7.83yrsUS$157.00k0.34% $209.5k
G. Fleming
Scientific Advisor7.83yrsUS$67.20kno data
Camillo Ricordi
Scientific Advisor7.25yrsUS$8.96kno data
Ashish Nanda
Independent Director3yrsUS$151.06kno data
Lorenzo Piemonti
Member Scientific Advisory Board1.83yrsno datano data

6.8yrs

Average Tenure

54yo

Average Age

Experienced Board: ORGS's board of directors are considered experienced (6.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.1%.


Top Shareholders

Company Information

Orgenesis Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Orgenesis Inc.
  • Ticker: ORGS
  • Exchange: NasdaqCM
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$60.775m
  • Shares outstanding: 18.36m
  • Website: https://www.orgenesis.com

Number of Employees


Location

  • Orgenesis Inc.
  • 20271 Goldenrod Lane
  • Germantown
  • Maryland
  • 20876
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ORGSNasdaqCM (Nasdaq Capital Market)YesCommon SharesUSUSDOct 2009
45OBST (Boerse-Stuttgart)YesCommon SharesDEEUROct 2009

Biography

Orgenesis Inc., a biotechnology company, engages in the development, manufacturing, and provision of services in the cell and gene therapy industry. The CDMO segment specializes in therapy development services, such as manufacturing and development services, and contract manufacturing services. The PT Business segment focuses on the development of proprietary cell and gene therapies, including the autologous trans-differentiation technology. It also has various collaboration and license agreements with Adva Biotechnology Ltd.; Tel Hashomer Medical Research, Infrastructure and Services Ltd; Mircod Limited; HekaBio K.K; Image Securities Ltd.; Hemogenyx Pharmaceuticals PLC.; Immugenyx LLC.; BG Negev Technologies and Applications; and Columbia University. The company was formerly known as Business Outsourcing Services, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was founded in 2008 and is based in Germantown, Maryland. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/31 01:26
End of Day Share Price2020/03/30 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.